InvestLog
FENC Fennec Pharmaceuticals Inc. logo

FENC Fennec Pharmaceuticals Inc.

Healthcare
$9.93-0.40%ClosedMarket Cap: $283.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

9.05

P/S

5.56

EV/EBITDA

-36.51

DCF Value

$-7.87

FCF Yield

-2.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.2%

Operating Margin

-11.0%

Net Margin

-16.4%

ROE

-55.1%

ROA

-11.7%

ROIC

-9.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$15.1M$201.0K$—
Q4 null$13.8M$-4.8M$—
FY null$44.6M$-9.7M$—
Q3 null$12.5M$-638.0K$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$16.00 - $18.00

2 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-05-22
WedbushOutperform
2026-04-16
HC Wainwright & Co.Buy
2025-08-21
Craig-HallumBuy
2025-08-15

Trading Activity

Insider Trades

View All
RALLIS CHRIS Adirector
SellTue May 12
RALLIS CHRIS Adirector
SellTue May 12
Sayad Pierre Sargisofficer: Chief Medical Officer
SellFri May 01
Raykov Rostydirector
SellFri May 01
Raykov Rostydirector
SellFri May 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.91

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Peers

AARD logoAARDAVTX logoAVTXBDTX logoBDTXCRBU logoCRBUENTA logoENTAEPRX logoEPRXNAUT logoNAUTOBIO logoOBIOPRLD logoPRLDRNAC logoRNAC